The Intriguing Thyroid Hormones–Lung Cancer Association as Exemplification of the Thyroid Hormones–Cancer Association: Three Decades of Evolving Research
Abstract
:1. Introduction
2. Synthesis, Metabolism, and Transport of TH
3. Molecular Aspects of the Actions of TH
4. The Contribution of TH to the “Hallmarks of Cancer”
5. Insights into the TH–Lung Cancer Association Gained over the Last Three Decades
5.1. Insights from Nonclinical Data
5.2. Insights from Clinical Data
6. Association of Non-Thyroidal Illness Syndrome (NTIS) with Lung Cancer
7. Current Challenges and Future Perspectives
8. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Conflicts of Interest
References
- Khatawkar, A.V.; Awati, S.M. Thyroid gland-Historical aspects, Embryology, Anatomy and Physiology. IAIM 2015, 2, 165–171. [Google Scholar]
- Salvatore, D.; Davies, T.; Sohlumberger, M.; Hay, I.; Larsen, P. Chapter 11-Thyroid Physiology and Diagnostic Evaluation of Patients with Thyroid Disorders. In Williams Textbook of Endocrinology, 12th ed.; Melmed, S., Koenig, R., Rosen, C., Auchus, R., Goldfine, A., Eds.; Elsevier Saunders: Philadelphia, PA, USA, 2011; pp. 327–361. [Google Scholar]
- Davis, P.J.; Leonard, J.L.; Lin, H.-Y.; Leinung, M.; Mousa, S.A. Molecular Basis of Nongenomic Actions of Thyroid Hormone. Vitam. Horm. 2018, 106, 67–96. [Google Scholar]
- Krashin, E.; Piekiełko-Witkowska, A.; Ellis, M.; Ashur-Fabian, O. Thyroid Hormones and Cancer: A Comprehensive Review of Preclinical and Clinical Studies. Front. Endocrinol. 2019, 10, 59. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sap, J.; Muñoz, A.; Damm, K.; Goldberg, Y.; Ghysdael, J.; Leutz, A.; Beug, H.; Vennström, B. The c-erb-A protein is a high-affinity receptor for thyroid hormone. Nature 1986, 324, 635–640. [Google Scholar] [CrossRef] [PubMed]
- Hercbergs, A.; Leith, J.T. Spontaneous Remission of Metastatic Lung Cancer Following Myxedema Coma--An Apoptosis-Related Phenomenon? J. Natl. Cancer Inst. 1993, 85, 1342–1343. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gauthier, B.R.; Sola-García, A.; Cáliz-Molina, M.Á.; Lorenzo, P.I.; Cobo-Vuilleumier, N.; Capilla-González, V.; Martin-Montalvo, A. Thyroid hormones in diabetes, cancer, and aging. Aging Cell 2020, 19, e13260. [Google Scholar] [CrossRef]
- Liu, Y.-C.; Yeh, C.-T.; Lin, K.-H. Molecular Functions of Thyroid Hormone Signaling in Regulation of Cancer Progression and Anti-Apoptosis. Int. J. Mol. Sci. 2019, 20, 4986. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef]
- Available online: https://seer.cancer.gov/statfacts/html/lungb.html (accessed on 12 October 2021).
- Available online: https://www.cancer.org/cancer/lung-cancer/about/what-is.html (accessed on 12 October 2021).
- Yuan, M.; Huang, L.-L.; Chen, J.-H.; Wu, J.; Xu, Q. The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduct. Target. Ther. 2019, 4, 1–14. [Google Scholar] [CrossRef] [Green Version]
- Hirsch, F.R.; Scagliotti, G.V.; Mulshine, J.L.; Kwon, R.; Curran, W.J., Jr.; Wu, Y.-L.; Paz-Ares, L. Lung cancer: Current therapies and new targeted treatments. Lancet 2017, 389, 299–311. [Google Scholar] [CrossRef]
- Howlader, N.; Forjaz, G.; Mooradian, M.J.; Meza, R.; Kong, C.Y.; Cronin, K.A.; Mariotto, A.B.; Lowy, D.R.; Feuer, E.J. The Effect of Advances in Lung-Cancer Treatment on Population Mortality. N. Engl. J. Med. 2020, 383, 640–649. [Google Scholar] [CrossRef] [PubMed]
- Farago, A.F.; Azzoli, C.G. Beyond ALK and ROS1: RET, NTRK, EGFR and BRAF gene rearrangements in non-small cell lung cancer. Transl. Lung Cancer Res. 2017, 6, 550–559. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, F.; Han, S.; Yang, J.; Yan, W.; Hu, G. Knowledge-Guided “Community Network” Analysis Reveals the Functional Modules and Candidate Targets in Non-Small-Cell Lung Cancer. Cells 2021, 10, 402. [Google Scholar] [CrossRef] [PubMed]
- Brahmer, J.; Reckamp, K.L.; Baas, P.; Crinò, L.; Eberhardt, W.E.E.; Poddubskaya, E.; Antonia, S.; Pluzanski, A.; Vokes, E.E.; Holgado, E.; et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer. N. Engl. J. Med. 2015, 373, 123–135. [Google Scholar] [CrossRef] [Green Version]
- Kazandjian, D.; Khozin, S.; Blumenthal, G.; Zhang, L.; Tang, S.; Libeg, M.; Kluetz, P.; Sridhara, R.; Keegan, P.; Pazdur, R. Benefit-Risk Summary of Nivolumab for Patients with Metastatic Squamous Cell Lung Cancer After Platinum-Based Chemotherapy: A Report from the US Food and Drug Administration. JAMA Oncol. 2016, 2, 118–122. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kazandjian, D.; Suzman, D.L.; Blumenthal, G.; Mushti, S.; He, K.; Libeg, M.; Keegan, P.; Pazdur, R. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer with Progression on or After Platinum-Based Chemotherapy. Oncologist 2016, 21, 634–642. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lim, S.M.; Hong, M.H.; Kim, H.R. Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives. Immune Netw. 2020, 20, e10. [Google Scholar] [CrossRef]
- Pakkala, S.; Ramalingam, S.S. Personalized therapy for lung cancer: Striking a moving target. JCI Insight 2018, 3, 120858. [Google Scholar] [CrossRef] [Green Version]
- Ding, P.; Ouyang, W.; Luo, J.; Kwoh, C.-K. Heterogeneous information network and its application to human health and disease. Brief. Bioinform. 2020, 21, 1327–1346. [Google Scholar] [CrossRef]
- Montesinos, M.D.M.; Pellizas, C.G. Thyroid Hormone Action on Innate Immunity. Front. Endocrinol. 2019, 10, 350. [Google Scholar] [CrossRef] [Green Version]
- Cooper, D.S.; Landenson, P.W. Chapter 7. The Thyroid Gland. In Greenspan’s Basic and Clinical Endocrinology, 9th ed.; Gardner, D., Shoback, D., Eds.; McGraw-Hill Education: New York, NY, USA, 2011; pp. 163–226. [Google Scholar]
- Saponaro, F.; Sestito, S.; Runfola, M.; Rapposelli, S.; Chiellini, G. Selective Thyroid Hormone Receptor-Beta (TRβ) Agonists: New Perspectives for the Treatment of Metabolic and Neurodegenerative Disorders. Front. Med. 2020, 7, 331. [Google Scholar] [CrossRef]
- Tancevski, I.; Rudling, M.; Eller, P. Thyromimetics: A journey from bench to bed-side. Pharmacol. Ther. 2011, 131, 33–39. [Google Scholar] [CrossRef]
- Moreno, M.; de Lange, P.; Lombardi, A.; Silvestri, E.; Lanni, A.; Goglia, F. Metabolic Effects of Thyroid Hormone Derivatives. Thyroid 2008, 18, 239–253. [Google Scholar] [CrossRef]
- Lin, H.-Y.; Tang, H.-Y.; Leinung, M.; Mousa, S.A.; Hercbergs, A.; Davis, P.J. Action of Reverse T3 on Cancer Cells. Endocr. Res. 2019, 44, 148–152. [Google Scholar] [CrossRef]
- Laurino, A.; Landucci, E.; Raimondi, L. Central Effects of 3-Iodothyronamine Reveal a Novel Role for Mitochondrial Monoamine Oxidases. Front. Endocrinol. 2018, 9, 290. [Google Scholar] [CrossRef] [PubMed]
- Louzada, R.A.; Carvalho, D.P. Similarities and Differences in the Peripheral Actions of Thyroid Hormones and Their Metabolites. Front. Endocrinol. 2018, 9, 394. [Google Scholar] [CrossRef] [PubMed]
- Senese, R.; de Lange, P.; Petito, G.; Moreno, M.; Goglia, F.; Lanni, A. 3,5-Diiodothyronine: A Novel Thyroid Hormone Metabolite and Potent Modulator of Energy Metabolism. Front. Endocrinol. 2018, 9, 427. [Google Scholar] [CrossRef]
- Giammanco, M.; di Liegro, C.M.; Schiera, G.; di Liegro, I. Genomic and Non-Genomic Mechanisms of Action of Thyroid Hormones and Their Catabolite 3,5-Diiodo-L-Thyronine in Mammals. Int. J. Mol. Sci. 2020, 21, 4140. [Google Scholar] [CrossRef] [PubMed]
- Ortiga-Carvalho, T.M.; Chiamolera, M.I.; Pazos-Moura, C.C.; Wondisford, F.E. Hypothalamus-pituitary-thyroid axis. Compr. Physiol. 2016, 6, 1387–1428. [Google Scholar]
- Mendoza, A.; Hollenberg, A.N. New insights into thyroid hormone action. Pharmacol. Ther. 2017, 173, 135–145. [Google Scholar] [CrossRef] [Green Version]
- Keestra, S.; Tabor, V.H.; Alvergne, A. Reinterpreting patterns of variation in human thyroid function: An evolu-tionary ecology perspective. Evol. Med. Public Health 2021, 9, 93–112. [Google Scholar] [CrossRef]
- Davis, F.B.; Cody, V.; Davis, P.J.; Borzynski, L.J.; Blas, S.D. Stimulation by thyroid hormone analogues of red blood cell Ca2+-ATPase activity in vitro. Correlations between hormone structure and biological activity in a human cell system. J. Biol. Chem. 1983, 258, 12373–12377. [Google Scholar] [CrossRef]
- Segal, J.; Ingbar, S.H. Evidence that an Increase in Cytoplasmic Calcium Is the Initiating Event in Certain Plasma Membrane-Mediated Responses to 3,5,3′-Triiodothyronine in Rat Thymocytes. Endocrinology 1989, 124, 1949–1955. [Google Scholar] [CrossRef]
- Segal, J.; Ingbar, S.H. 3,5,3′-Tri-iodothyronine enhances sugar transport in rat thymocytes by increasing the intrinsic activity of the plasma membrane sugar transporter. J. Endocrinol. 1990, 124, 133–140. [Google Scholar] [CrossRef] [PubMed]
- Siegrist-Kaiser, C.A.; Juge-Aubry, C.; Tranter, M.P.; Ekenbarger, D.M.; Leonard, J.L. Thyroxine-dependent modulation of actin polymerization in cultured astrocytes. A novel, extranuclear action of thyroid hormone. J. Biol. Chem. 1990, 265, 5296–5302. [Google Scholar] [CrossRef]
- Sterling, K.; Brenner, M.A.; Sakurada, T. Rapid Effect of Triiodothyronine on the Mitochondrial Pathway in Rat Liver In Vivo. Science 1980, 210, 340–342. [Google Scholar] [CrossRef] [PubMed]
- Flamant, F.; Cheng, S.-Y.; Hollenberg, A.N.; Moeller, L.C.; Samarut, J.; Wondisford, F.E.; Yen, P.M.; Refetoff, S. Thyroid Hormone Signaling Pathways: Time for a More Precise Nomenclature. Endocrinology 2017, 158, 2052–2057. [Google Scholar] [CrossRef]
- Weikum, E.R.; Liu, X.; Ortlund, E.A. The nuclear receptor superfamily: A structural perspective. Protein Sci. 2018, 27, 1876–1892. [Google Scholar] [CrossRef] [PubMed]
- Cheng, S.-Y.; Leonard, J.L.; Davis, P.J. Molecular Aspects of Thyroid Hormone Actions. Endocr. Rev. 2010, 31, 139–170. [Google Scholar] [CrossRef] [Green Version]
- de Luca, R.; Davis, P.J.; Lin, H.-Y.; Gionfra, F.; Percario, Z.A.; Affabris, E.; Pedersen, J.Z.; Marchese, C.; Trivedi, P.; Anastasiadou, E.; et al. Thyroid Hormones Interaction with Immune Response, Inflammation and Non-thyroidal Illness Syndrome. Front. Cell Dev. Biol. 2021, 8, 614030. [Google Scholar] [CrossRef]
- Zhang, J.; Roggero, V.R.; Allison, L.A. Nuclear Import and Export of the Thyroid Hormone Receptor. Vitam. Horm. 2018, 106, 45–66. [Google Scholar] [PubMed]
- Nakano, K.; Matsushita, A.; Sasaki, S.; Misawa, H.; Nishiyama, K.; Kashiwabara, Y.; Nakamura, H. Thyroid-hormone-dependent negative regulation of thyrotropin beta gene by thyroid hormone receptors: Study with a new experimental system using CV1 cells. Biochem. J. 2004, 378, 549–557. [Google Scholar] [CrossRef]
- Weitzel, J.M. To bind or not to bind—How to down-regulate target genes by liganded thyroid hormone receptor? Thyroid. Res. 2008, 1, 1–5. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kashiwabara, Y.; Sasaki, S.; Matsushita, A.; Nagayama, K.; Ohba, K.; Iwaki, H.; Matsunaga, H.; Suzuki, S.; Misawa, H.; Ishizuka, K.; et al. Functions of PIT1 in GATA2-dependent transactivation of the thyrotropin β promoter. J. Mol. EnDocrinol. 2009, 42, 225–237. [Google Scholar] [CrossRef]
- Fonseca, T.L.; Correa-Medina, M.; Campos, M.P.O.; Wittmann, G.; Werneck-de-Castro, J.P.; e Drigo, R.A.; Mora-Garzon, M.; Ueta, C.B.; Caicedo, A.; Fekete, C.; et al. Coordination of hypothalamic and pituitary T3 production regulates TSH expression. J. Clin. Investig. 2013, 123, 1492–1500. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Matsunaga, H.; Sasaki, S.; Suzuki, S.; Matsushita, A.; Nakamura, H.; Nakamura, H.M.; Hirahara, N.; Kuroda, G.; Iwaki, H.; Ohba, K.; et al. Essential Role of GATA2 in the Negative Regulation of Type 2 Deiodinase Gene by Liganded Thyroid Hormone Receptor β2 in Thyrotroph. PLoS ONE 2015, 10, e0142400. [Google Scholar] [CrossRef] [Green Version]
- Davis, F.B.; Mousa, S.A.; O’Connor, L.; Mohamed, S.; Lin, H.-Y.; Cao, H.J.; Davis, P.J. Proangiogenic Action of Thyroid Hormone Is Fibroblast Growth Factor–Dependent and Is Initiated at the Cell Surface. Circ. Res. 2004, 94, 1500–1506. [Google Scholar] [CrossRef]
- Bergh, J.J.; Lin, H.Y.; Lansing, L.; Mohamed, S.N.; Davis, F.B.; Mousa, S.; Davis, P.J. Integrin alphaVbeta3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. Endocrinology 2005, 146, 2864–2871. [Google Scholar] [CrossRef]
- Havaki, S.; Kouloukoussa, M.; Amawi, K.; Drosos, Y.; Arvanitis, L.D.; Goutas, N.; Vlachodimitropoulos, D.; Vassilaros, S.D.; Katsantoni, E.Z.; Voloudakis-Baltatzis, I.; et al. Altered expression pattern of integrin alphavbeta3 correlates with actin cytoskeleton in primary cultures of human breast cancer. Cancer Cell Int. 2007, 7, 16. [Google Scholar] [CrossRef] [Green Version]
- Saltel, F.; Chabadel, A.; Bonnelye, E.; Jurdic, P. Actin cytoskeletal organisation in osteoclasts: A model to decipher transmigration and matrix degradation. Eur. J. Cell Biol. 2008, 87, 459–468. [Google Scholar] [CrossRef] [PubMed]
- Koutsioumpa, M.; Polytarchou, C.; Courty, J.; Zhang, Y.; Kieffer, N.; Mikelis, C.; Skandalis, S.S.; Hellman, U.; Iliopoulos, D.; Papadimitriou, E. Interplay between αvβ3 Integrin and Nucleolin Regulates Human Endothelial and Glioma Cell Migration. J. Biol. Chem. 2013, 288, 343–354. [Google Scholar] [CrossRef] [Green Version]
- Colin, D.; Limagne, E.; Jeanningros, S.; Jacquel, A.; Lizard, G.; Athias, A.; Gambert, P.; Hichami, A.; Latruffe, N.; Solary, E.; et al. Endocytosis of Resveratrol via Lipid Rafts and Activation of Downstream Signaling Pathways in Cancer Cells. Cancer Prev. Res. 2011, 4, 1095–1106. [Google Scholar] [CrossRef] [Green Version]
- Reuning, U. Integrin αvβ3 promotes vitronectin gene expression in human ovarian cancer cells by implicating rel transcription factors. J. Cell. Biochem. 2011, 112, 1909–1919. [Google Scholar] [CrossRef]
- Umemoto, T.; Yamato, M.; Ishihara, J.; Shiratsuchi, Y.; Utsumi, M.; Morita, Y.; Tsukui, H.; Terasawa, M.; Shibata, T.; Nishida, K.; et al. Integrin-αvβ3 regulates thrombopoietin-mediated maintenance of hematopoietic stem cells. Blood 2012, 119, 83–94. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Roth, P.; Silginer, M.; Goodman, S.L.; Hasenbach, K.; Thies, S.; Maurer, G.; Schraml, P.; Tabatabai, G.; Moch, H.; Tritschler, I.; et al. Integrin control of the transforming growth factor-β pathway in glioblastoma. Brain 2013, 136, 564–576. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cody, V.; Davis, P.J.; Davis, F.B. Molecular modeling of the thyroid hormone interactions with alpha v beta 3 integrin. Steroids 2007, 72, 165–170. [Google Scholar] [CrossRef]
- Ho, Y.; Li, Z.-L.; Shih, Y.-J.; Chen, Y.-R.; Wang, K.; Whang-Peng, J.; Lin, H.-Y.; Davis, P.J. Integrin αvβ3 in the Mediating Effects of Dihydrotestosterone and Resveratrol on Breast Cancer Cell Proliferation. Int. J. Mol. Sci. 2020, 21, 2906. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Davis, P.J.; Davis, F.B.; Mousa, S.A.; Luidens, M.K.; Lin, H.Y. Membrane receptor for thyroid hormone: Physiologic and phar-macologic implications. Annu. Rev. Pharmacol. Toxicol. 2011, 51, 99–115. [Google Scholar] [CrossRef]
- Hercbergs, A. Clinical Implications and Impact of Discovery of the Thyroid Hormone Receptor on Integrin αvβ3—A Review. Front. Endocrinol. 2019, 10, 565. [Google Scholar] [CrossRef] [Green Version]
- Davis, P.J.; Mousa, S.A.; Schechter, G.P.; Lin, H.-Y. Platelet ATP, Thyroid Hormone Receptor on Integrin αvβ3 and Cancer Metastasis. Horm. Cancer 2020, 11, 13–16. [Google Scholar] [CrossRef]
- Davis, P.J.; Leonard, J.L.; Davis, F.B. Mechanisms of nongenomic actions of thyroid hormone. Front. Neuroendocr. 2008, 29, 211–218. [Google Scholar] [CrossRef]
- Davis, P.J.; Glinsky, G.V.; Lin, H.-Y.; Leith, J.T.; Hercbergs, A.; Tang, H.-Y.; Ashur-Fabian, O.; Incerpi, S.; Mousa, S.A. Cancer Cell Gene Expression Modulated from Plasma Membrane Integrin αvβ3 by Thyroid Hormone and Nanoparticulate Tetrac. Front. Endocrinol. 2015, 5, 240. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Davis, P.J.; Mousa, S.A.; Lin, H.-Y. Nongenomic Actions of Thyroid Hormone: The Integrin Component. Physiol. Rev. 2021, 101, 319–352. [Google Scholar] [CrossRef]
- Huang, T.-Y.; Chang, T.-C.; Chin, Y.-T.; Pan, Y.-S.; Chang, W.-J.; Liu, F.-C.; Hastuti, E.D.; Chiu, S.-J.; Wang, S.-H.; Changou, C.A.; et al. NDAT Targets PI3K-Mediated PD-L1 Upregulation to Reduce Proliferation in Gefitinib-Resistant Colorectal Cancer. Cells 2020, 9, 1830. [Google Scholar] [CrossRef] [PubMed]
- Davis, P.J.; Goglia, F.; Leonard, J. L Nongenomic actions of thyroid hormone. Nat. Rev. Endocrinol. 2016, 12, 111–121. [Google Scholar] [CrossRef]
- Ashur-Fabian, O.; Zloto, O.; Fabian, I.; Tsarfaty, G.; Ellis, M.; Steinberg, D.M.; Hercbergs, A.; Davis, P.J.; Fabian, I.D. Tetrac Delayed the Onset of Ocular Melanoma in an Orthotopic Mouse Model. Front. Endocrinol. 2019, 9, 775. [Google Scholar] [CrossRef]
- Davis, P.J.; Incerpi, S.; Lin, H.-Y.; Tang, H.-Y.; Sudha, T.; Mousa, S.A. Thyroid Hormone and P-Glycoprotein in Tumor Cells. BioMed Res. Int. 2015, 2015, 1–8. [Google Scholar] [CrossRef]
- Hallen, A.; Cooper, A.J.L.; Jamie, J.F.; Karuso, P. Insights into Enzyme Catalysis and Thyroid Hormone Regulation of Cerebral Ketimine Reductase/μ-Crystallin Under Physiological Conditions. Neurochem. Res. 2015, 40, 1252–1266. [Google Scholar] [CrossRef] [PubMed]
- Goemann, I.M.; Romitti, M.; Meyer, E.L.S.; Wajner, S.M.; Maia, A.L. Role of thyroid hormones in the neoplastic process: An overview. Endocr. Relat. Cancer 2017, 24, R367–R385. [Google Scholar] [CrossRef]
- Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell 2000, 100, 57–70. [Google Scholar] [CrossRef] [Green Version]
- Hanahan, D.; Weinberg, R.A. Hallmarks of Cancer: The Next Generation. Cell 2011, 144, 646–674. [Google Scholar] [CrossRef] [Green Version]
- Chen, C.-Y.; Chung, I.-H.; Tsai, M.-M.; Tseng, Y.-H.; Chi, H.-C.; Tsai, C.-Y.; Lin, Y.-H.; Wang, Y.-C.; Chen, C.-P.; Wu, T.-I.; et al. Thyroid hormone enhanced human hepatoma cell motility involves brain-specific serine protease 4 activation via ERK signaling. Mol. Cancer 2014, 13, 162. [Google Scholar] [CrossRef] [Green Version]
- Lin, Y.-H.; Liao, C.-J.; Huang, Y.-H.; Wu, M.-H.; Chi, H.-C.; Wu, S.-M.; Chen, C.-Y.; Tseng, Y.-H.; Tsai, C.-Y.; Chung, I.-H.; et al. Thyroid hormone receptor represses miR-17 expression to enhance tumor metastasis in human hepatoma cells. Oncogene 2013, 32, 4509–4518. [Google Scholar] [CrossRef] [Green Version]
- Lin, Y.-H.; Wu, M.-H.; Liao, C.-J.; Huang, Y.-H.; Chi, H.-C.; Wu, S.-M.; Chen, C.-Y.; Tseng, Y.-H.; Tsai, C.-Y.; Chung, I.-H.; et al. Repression of microRNA-130b by thyroid hormone enhances cell motility. J. Hepatol. 2015, 62, 1328–1340. [Google Scholar] [CrossRef]
- Huang, S.A.; Tu, H.M.; Harney, J.W.; Venihaki, M.; Butte, A.J.; Kozakewich, H.P.W.; Fishman, S.J.; Larsen, P.R. Severe Hypothyroidism Caused by Type 3 Iodothyronine Deiodinase in Infantile Hemangiomas. N. Engl. J. Med. 2000, 343, 185–189. [Google Scholar] [CrossRef]
- Liao, C.-H.; Yeh, S.-C.; Huang, Y.-H.; Chen, R.-N.; Tsai, M.-M.; Chen, W.-J.; Chi, H.-C.; Tai, P.-J.; Liao, C.-J.; Wu, S.-M.; et al. Positive regulation of spondin 2 by thyroid hormone is associated with cell migration and invasion. Endocr. Relat. Cancer 2010, 17, 99–111. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chi, H.-C.; Liao, C.-H.; Huang, Y.-H.; Wu, S.-M.; Tsai, C.-Y.; Liao, C.-J.; Tseng, Y.-H.; Lin, Y.-H.; Chen, C.-Y.; Chung, I.-H.; et al. Thyroid hormone receptor inhibits hepatoma cell migration through transcriptional activation of Dickkopf 4. Biochem. Biophys. Res. Commun. 2013, 439, 60–65. [Google Scholar] [CrossRef] [PubMed]
- Liao, C.-H.; Yeh, C.-T.; Huang, Y.-H.; Wu, S.-M.; Chi, H.-C.; Tsai, M.-M.; Tsai, C.-Y.; Liao, C.-J.; Tseng, Y.-H.; Lin, Y.-H.; et al. Dickkopf 4 positively regulated by the thyroid hormone receptor suppresses cell invasion in human hepatoma cells. Hepatolology 2012, 55, 910–920. [Google Scholar] [CrossRef]
- Suhane, S.; Ramanujan, V.K. Thyroid hormone differentially modulates Warburg phenotype in breast cancer cells. Biochem. Biophys. Res. Commun. 2011, 414, 73–78. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kowalik, M.A.; Puliga, E.; Cabras, L.; Sulas, P.; Petrelli, A.; Perra, A.; Ledda-Columbano, G.M.; Morandi, A.; Merlin, S.; Orrù, C.; et al. Thyroid hormone inhibits hepatocellular carcinoma progression via induction of differentiation and metabolic reprogramming. J. Hepatol. 2020, 72, 1159–1169. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lin, H.-Y.; Chin, Y.-T.; Nana, A.W.; Shih, Y.-J.; Lai, H.-Y.; Tang, H.-Y.; Leinung, M.; Mousa, S.A.; Davis, P.J. Actions of l-thyroxine and Nano-diamino-tetrac (Nanotetrac) on PD-L1 in cancer cells. Steroids 2016, 114, 59–67. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Perrotta, C.; Buldorini, M.; Assi, E.; Cazzato, D.; de Palma, C.; Clementi, E.; Cervia, D. The thyroid hormone triiodothyronine controls macrophage maturation and functions: Protective role during inflammation. Am. J. Pathol. 2014, 184, 230–247. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Szabó, J.; Fóris, G.; Mezösi, E.; Nagy, E.V.; Paragh, G.; Sztojka, I.; Leövey, A. Parameters of respiratory burst and arachidonic acid metabolism in polymorphonuclear granulocytes from patients with various thyroid diseases. Exp. Clin. Endocrinol. Diabetes 1996, 104, 172–176. [Google Scholar] [CrossRef]
- Provinciali, M.; Fabris, N. Modulation of lymphoid cell sensitivity to interferon by thyroid hormones. J. Endocrinol. Investig. 1990, 13, 187–191. [Google Scholar] [CrossRef] [PubMed]
- Lee, E.K.; Sunwoo, J.B. Natural Killer Cells and Thyroid Diseases. Endocrinol. Metab. 2019, 34, 132–137. [Google Scholar] [CrossRef]
- Schmohl, K.A.; Müller, A.M.; Wechselberger, A.; Rühland, S.; Salb, N.; Schwenk, N.; Heuer, H.; Carlsen, J.; Göke, B.; Nelson, P.J.; et al. Thyroid hormones and tetrac: New regulators of tumour stroma formation via integrin αvβ3. Endocr. Relat. Cancer 2015, 22, 941–952. [Google Scholar] [CrossRef] [Green Version]
- Zambrano, A.; García-Carpizo, V.; Gallardo, M.E.; Villamuera, R.; Gómez-Ferrería, M.A.; Pascual, A.; Buisine, N.; Sachs, L.M.; Garesse, R.; Aranda, A. The thyroid hormone receptor β induces DNA damage and premature senescence. J. Cell Biol. 2014, 204, 129–146. [Google Scholar] [CrossRef] [Green Version]
- Hoare, M.; Narita, M. The Power behind the Throne: Senescence and the Hallmarks of Cancer. Annu. Rev. Cancer Biol. 2018, 2, 175–194. [Google Scholar] [CrossRef] [Green Version]
- Kinoshita, S.; Sone, S.; Yamashita, T.; Tsubura, E.; Ogura, T. Effects of experimental hyper- and hypothyroidism on natural defense activities against Lewis lung carcinoma and its spontaneous pulmonary metastases in C57BL/6 mice. Tokushima J. Exp. Med. 1991, 38, 25–35. [Google Scholar]
- Theodossiou, C.; Skrepnik, N.; Robert, E.G.; Prasad, C.; Axelrad, T.W.; Schapira, D.V.; Hunt, J.D. Propylthiouracil-induced hypothyroidism reduces xenograft tumor growth in athymic nude mice. Cancer 1999, 86, 1596–1601. [Google Scholar] [CrossRef]
- Iwasaki, Y.; Sunaga, N.; Tomizawa, Y.; Imai, H.; Iijima, H.; Yanagitani, N.; Horiguchi, K.; Yamada, M.; Mori, M. Epigenetic inactivation of the thyroid hormone receptor beta1 gene at 3p24.2 in lung cancer. Ann. Surg. Oncol. 2010, 17, 2222–2228. [Google Scholar] [CrossRef]
- Meng, R.; Tang, H.-Y.; Westfall, J.; London, D.; Cao, J.H.; Mousa, S.A.; Luidens, M.; Hercbergs, A.; Davis, F.B.; Davis, P.J.; et al. Crosstalk between Integrin αvβ3 and Estrogen Receptor-α Is Involved in Thyroid Hormone-Induced Proliferation in Human Lung Carcinoma Cells. PLoS ONE 2011, 6, e27547. [Google Scholar] [CrossRef] [PubMed]
- Mousa, S.A.; Yalcin, M.; Bharali, D.J.; Meng, R.; Tang, H.-Y.; Lin, H.-Y.; Davis, F.B.; Davis, P.J. Tetraiodothyroacetic acid and its nanoformulation inhibit thyroid hormone stimulation of non-small cell lung cancer cells in vitro and its growth in xenografts. Lung Cancer 2012, 76, 39–45. [Google Scholar] [CrossRef] [PubMed]
- Lin, H.-Y.; Su, Y.-F.; Hsieh, M.-T.; Lin, S.; Meng, R.; London, D.; Lin, C.; Tang, H.-Y.; Hwang, J.; Davis, F.B.; et al. Nuclear monomeric integrin αv in cancer cells is a coactivator regulated by thyroid hormone. FASEB J. 2013, 27, 3209–3216. [Google Scholar] [CrossRef]
- Carmona-Cortés, J.; Rodríguez-Gómez, I.; Wangensteen, R.; Banegas, I.; García-Lora, Á.M.; Quesada, A.; Osuna, A.; Vargas, F. Effect of thyroid hormone–nitric oxide interaction on tumor growth, angiogenesis, and aminopeptidase activity in mice. Tumour Biol. 2014, 35, 5519–5526. [Google Scholar] [CrossRef]
- Latteyer, S.; Christoph, S.; Theurer, S.; Hönes, G.S.; Schmid, K.W.; Führer, D.; Moeller, L.C. Thyroxine promotes lung cancer growth in an orthotopic mouse model. Endocr. Relat. Cancer 2019, 26, 565–574. [Google Scholar] [CrossRef]
- Hercbergs, A.; Mason, J.; Reddy, C.; Elson, P. Thyroid hormones and lung cancer: Primary hypothyroidism is prognostically significant for survival in lung cancer. Cancer Res. 2004, 64, 1024. [Google Scholar]
- Mazzoccoli, G.; Pazienza, V.; Piepoli, A.; Muscarella, L.A.; Giuliani, F.; Sothern, R.B. Alteration of Hypothalamic–Pituitary–Thyroid Axis Function in Non-Small-Cell Lung Cancer Patients. Integr. Cancer Ther. 2012, 11, 327–336. [Google Scholar] [CrossRef] [Green Version]
- Hellevik, A.I.; Åsvold, B.O.; Bjøro, T.; Romundstad, P.; Nilsen, T.I.L.; Vatten, L.J. Thyroid Function and Cancer Risk: A Prospective Population Study. Cancer Epidemiol. Biomark. Prev. 2009, 18, 570–574. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Khan, S.R.; Chaker, L.; Ruiter, R.; Aerts, J.G.J.V.; Hofman, A.; Dehghan, A.; Franco, O.H.; Stricker, B.H.C.; Peeters, R.P. Thyroid Function and Cancer Risk: The Rotterdam Study. J. Clin. Endocrinol. Metab. 2016, 101, 5030–5036. [Google Scholar] [CrossRef]
- Chan, Y.X.; Knuiman, M.W.; Divitini, M.L.; Brown, S.J.; Walsh, J.; Yeap, B.B. Lower TSH and higher free thyroxine predict incidence of prostate but not breast, colorectal or lung cancer. Eur. J. Endocrinol. 2017, 177, 297–308. [Google Scholar] [CrossRef] [Green Version]
- Cornelli, U.; Belcaro, G.; Recchia, M.; Finco, A. Levothyroxine and lung cancer in females: The importance of oxidative stress. Reprod. Biol. Endocrinol. 2013, 11, 75. [Google Scholar] [CrossRef] [Green Version]
- Bhattacharya, S.; Goyal, A.; Kaur, P.; Singh, R.; Kalra, S. Anticancer Drug-induced Thyroid Dysfunction. Eur. Endocrinol. 2020, 16, 32–39. [Google Scholar] [CrossRef] [PubMed]
- El Sabbagh, R.; Azar, N.S.; Eid, A.A.; Azar, S.T. Thyroid Dysfunctions Due to Immune Checkpoint Inhibitors: A Review. Int. J. Gen. Med. 2020, 13, 1003–1009. [Google Scholar] [CrossRef] [PubMed]
- Lee, H.; Hodi, F.S.; Giobbie-Hurder, A.; Ott, P.A.; Buchbinder, E.I.; Haq, R.; Tolaney, S.; Barroso-Sousa, R.; Zhang, K.; Donahue, H.; et al. Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy. Cancer Immunol. Res. 2017, 5, 1133–1140. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Illouz, F.; Drui, D.; Caron, P.; Cao, C.D. Expert opinion on thyroid complications in immunotherapy. Ann. D’endocrinologie 2018, 79, 555–561. [Google Scholar] [CrossRef] [PubMed]
- Chalan, P.; di Dalmazi, G.; Pani, F.; de Remigis, A.; Corsello, A.; Caturegli, P. Thyroid dysfunctions secondary to cancer immunotherapy. J. Endocrinol. Investig. 2018, 41, 625–638. [Google Scholar] [CrossRef]
- Kurimoto, C.; Inaba, H.; Ariyasu, H.; Iwakura, H.; Ueda, Y.; Uraki, S.; Takeshima, K.; Furukawa, Y.; Morita, S.; Yamamoto, Y.; et al. Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors. Cancer Sci. 2020, 111, 1468–1477. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Osorio, J.C.; Ni, A.; Chaft, J.E.; Pollina, R.; Kasler, M.K.; Stephens, D.; Rodriguez, C.; Cambridge, L.; Rizvi, H.; Wolchok, J.D.; et al. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann. Oncol. 2017, 28, 583–589. [Google Scholar] [CrossRef]
- Thuillier, P.; Joly, C.; Alavi, Z.; Crouzeix, G.; Descourt, R.; Quere, G.; Kerlan, V.; Roudaut, N. Thyroid dysfunction induced by immune checkpoint inhibitors is associated with a better progression-free survival and overall survival in non-small cell lung cancer: An original cohort study. Cancer Immunol. Immunother. 2021, 70, 2023–2033. [Google Scholar] [CrossRef] [PubMed]
- Funazo, T.Y.; Nomizo, T.; Ozasa, H.; Tsuji, T.; Yasuda, Y.; Yoshida, H.; Sakamori, Y.; Nagai, H.; Hirai, T.; Kim, Y.H. Clinical impact of low serum free T4 in patients with non-small cell lung cancer treated with nivolumab. Sci. Rep. 2019, 9, 1–8. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sbardella, E.; Tenuta, M.; Sirgiovanni, G.; Gianfrilli, D.; Pozza, C.; Venneri, M.A.; Cortesi, E.; Marchetti, P.; Lenzi, A.; Gelibter, A.J.; et al. Thyroid disorders in programmed death 1 inhibitor-treated patients: Is previous therapy with tyrosine kinase inhibitors a predisposing factor? Clin. Endocrinol. 2020, 92, 258–265. [Google Scholar] [CrossRef] [PubMed]
- Ahmadieh, H.; Salti, I. Tyrosine Kinase Inhibitors Induced Thyroid Dysfunction: A Review of Its Incidence, Pathophysiology, Clinical Relevance, and Treatment. BioMed Res. Int. 2013, 2013, 725410. [Google Scholar] [CrossRef] [Green Version]
- Funakoshi, T.; Shimada, Y.J. Risk of hypothyroidism in patients with cancer treated with sunitinib: A systematic review and meta-analysis. Acta Oncol. 2013, 52, 691–702. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Makita, N.; Iiri, T. Tyrosine Kinase Inhibitor–Induced Thyroid Disorders: A Review and Hypothesis. Thyroid 2013, 23, 151–159. [Google Scholar] [CrossRef]
- Soni, S.; Rastogi, A.; Prasad, K.T.; Behera, D.; Singh, N. Thyroid dysfunction in non-small cell lung cancer patients treated with epidermal growth factor receptor and anaplastic lymphoma kinase inhibitors: Results of a prospective cohort. Lung Cancer 2021, 151, 16–19. [Google Scholar] [CrossRef]
- Bilen, M.A.; Patel, A.; Hess, K.R.; Munoz, J.; Busaidy, N.L.; Wheler, J.J.; Janku, F.; Falchook, G.S.; Hong, D.S.; Meric-Bernstam, F.; et al. Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials. Cancer Chemother. Pharmacol. 2016, 78, 167–171. [Google Scholar] [CrossRef]
- Si, X.; Zhang, L.; Wang, H.; Zhang, X.; Wang, M.; Han, B.; Li, K.; Wang, Q.; Shi, J.; Wang, Z.; et al. Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303. Thorac. Cancer 2019, 10, 551–556. [Google Scholar] [CrossRef] [Green Version]
- DeGroot, L.J. The Non-Thyroidal Illness Syndrome. In Endotext; Feingold, K.R., Anawalt, B., Eds.; MDText.com, Inc.: South Dartmouth, MA, USA, 2000. Available online: https://www.ncbi.nlm.nih.gov/books/NBK285570/ (accessed on 10 September 2021).
- Schwarz, Y.; Percik, R.; Oberman, B.; Yaffe, D.; Zimlichman, E.; Tirosh, A. Sick Euthyroid Syndrome on Presentation of Patients with COVID-19: A Potential Marker for Disease Severity. Endocr. Pract. 2021, 27, 101–109. [Google Scholar] [CrossRef]
- Ratcliffe, J.G.; Stack, B.H.R.; Burt, R.W.; Ratcliffe, W.A.; Spilg, W.G.S.; Cuthbert, J.; Kennedy, R.S. Thyroid function in lung cancer. Br. Med. J. 1978, 1, 210–212. [Google Scholar] [CrossRef] [Green Version]
- EkremCengiz, S.; Cetinkaya, E.; Altin, S.; Gunluoglu, Z.; Demir, A.; Gunluoglu, G.; Epozturk, K. Nutritional and Prognostic Significance of Sick Euthyroid Syndrome in Non-small Cell Lung Cancer Patients. Intern. Med. 2008, 47, 211–216. [Google Scholar] [CrossRef] [Green Version]
- Yasar, Z.A.; Kirakli, C.; Yilmaz, U.; Ucar, Z.Z.; Talay, F. Can Non-Thyroid Illness Syndrome Predict Mortality in Lung Cancer Patients? A Prospective Cohort Study. Horm. Cancer 2014, 5, 240–246. [Google Scholar] [CrossRef]
- Al-Farsi, A.; Ellis, P.M. Treatment Paradigms for Patients with Metastatic Non-Small Cell Lung Cancer, Squamous Lung Cancer: First, Second, and Third-Line. Front. Oncol. 2014, 4, 157. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hijazo-Pechero, S.; Alay, A.; Marín, R.; Vilariño, N.; Muñoz-Pinedo, C.; Villanueva, A.; Santamaría, D.; Nadal, E.; Solé, X. Gene Expression Profiling as a Potential Tool for Precision Oncology in Non-Small Cell Lung Cancer. Cancers 2021, 13, 4734. [Google Scholar] [CrossRef] [PubMed]
- Nixon, A.B.; Schalper, K.A.; Jacobs, I.; Potluri, S.; Wang, I.-M.; Fleener, C. Peripheral immune-based biomarkers in cancer immunotherapy: Can we realize their predictive potential? J. Immunother. Cancer 2019, 7, 325. [Google Scholar] [CrossRef]
- Schiera, G.; di Liegro, C.M.; di Liegro, I. Involvement of Thyroid Hormones in Brain Development and Cancer. Cancers 2021, 13, 2693. [Google Scholar] [CrossRef]
- Piras, C.; Pibiri, M.; Leoni, V.P.; Balsamo, A.; Tronci, L.; Arisci, N.; Mariotti, S.; Atzori, L. Analysis of metabolomics profile in hypothyroid patients before and after thyroid hormone replacement. J. Endocrinol. Investig. 2021, 44, 1309–1319. [Google Scholar] [CrossRef]
- Available online: https://clinicaltrials.gov/ct2/show/NCT03823859 (accessed on 10 September 2021).
- Rodríguez-Molinero, A.; Hercbergs, A.; Sarrias, M.; Yuste, A. Plasma 3,3′,5-Triiodo-L-thyronine [T3] level mirrors changes in tumor markers in two cases of metastatic cancer of the breast and pancreas treated with exogenous L-T3. Cancer Biomark. 2018, 21, 433–438. [Google Scholar] [CrossRef] [Green Version]
- Zhou, X.; Jiao, L.; Qian, Y.; Dong, Q.; Sun, Y.; Zheng, W.V.; Zhao, W.; Zhai, W.; Qiu, L.; Wu, Y.; et al. Repositioning Azelnidipine as a Dual Inhibitor Targeting CD47/SIRPα and TIGIT/PVR Pathways for Cancer Immuno- Therapy. Biomolecules 2021, 11, 706. [Google Scholar] [CrossRef]
- Stevens, D.; Ingels, J.; Van Lint, S.; Vandekerckhove, B.; Vermaelen, K. Dendritic Cell-Based Immunotherapy in Lung Cancer. Front. Immunol. 2021, 11, 620374. [Google Scholar] [CrossRef] [PubMed]
- Huang, J.; Ji, G.; Xing, L.; Li, H.; Wang, Z.; Ren, G.; Wu, K.; Kong, L. Neo-endocrinochemotherapy: A novel approach for enhancing chemotherapeutic efficacy in clinic? Med. Hypotheses 2013, 80, 441–446. [Google Scholar] [CrossRef]
- van Tassell, B.; Wohlford, G.F., IV; Linderman, J.D.; Smith, S.; Yavuz, S.; Pucino, F.; Celi, F.S. Pharmacokinetics of L-Triiodothyronine in Patients Undergoing Thyroid Hormone Therapy Withdrawal. Thyroid 2019, 29, 1371–1379. [Google Scholar] [CrossRef] [Green Version]
- Columbano, A.; Chiellini, G.; Kowalik, M.A. GC-1: A Thyromimetic with Multiple Therapeutic Applications in Liver Disease. Gene Expr. 2017, 17, 265–275. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Köhrle, J.; Lehmphul, I.; Pietzner, M.; Renko, K.; Rijntjes, E.; Richards, K.; Anselmo, J.; Danielsen, M.; Jonklaas, J. 3,5-T2—A Janus-Faced Thyroid Hormone Metabolite Exerts Both Canonical T3-Mimetic Endocrine and Intracrine Hepatic Action. Front. Endocrinol. 2020, 10, 787. [Google Scholar] [CrossRef]
- Leith, J.T.; Mousa, S.A.; Hercbergs, A.; Lin, H.Y.; Davis, P.J. Radioresistance of cancer cells, integrin αvβ3 and thyroid hormone. Oncotarget 2018, 9, 37069–37075. [Google Scholar] [CrossRef] [Green Version]
- Moossavi, M.; Parsamanesh, N.; Bahrami, A.; Atkin, S.L.; Sahebkar, A. Role of the NLRP3 inflammasome in cancer. Mol. Cancer 2018, 17, 158. [Google Scholar] [CrossRef] [Green Version]
- Glinskii, A.B.; Glinsky, G.V.; Lin, H.-Y.; Tang, H.-Y.; Sun, M.; Davis, F.B.; Luidens, M.K.; Mousa, S.A.; Hercbergs, A.H.; Davis, P.J. Modification of survival pathway gene expression in human breast cancer cells by tetraiodothyroacetic acid (tetrac). Cell Cycle 2009, 8, 3562–3570. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ahmadi, R.; Ebrahimzadeh, M.A. Resveratrol–A comprehensive review of recent advances in anticancer drug design and development. Eur. J. Med. Chem. 2020, 200, 112356. [Google Scholar] [CrossRef]
- Gorvel, L.; Olive, D. Targeting the “PVR-TIGIT axis” with immune checkpoint therapies. F1000Research 2020, 9, 354. [Google Scholar] [CrossRef]
- Ghimessy, A.; Radeczky, P.; Laszlo, V.; Hegedus, B.; Renyi-Vamos, F.; Fillinger, J.; Klepetko, W.; Lang, C.; Dome, B.; Megyesfalvi, Z. Current therapy of KRAS-mutant lung cancer. Cancer Metastasis Rev. 2020, 39, 1159–1177. [Google Scholar] [CrossRef] [PubMed]
- Yang, H.; Liang, S.-Q.; Schmid, R.A.; Peng, R.-W. New Horizons in KRAS-Mutant Lung Cancer: Dawn after Darkness. Front. Oncol. 2019, 9, 953. [Google Scholar] [CrossRef] [Green Version]
- Ruggeri, R.M.; Campennì, A.; Deandreis, D.; Siracusa, M.; Tozzoli, R.; Ovčariček, P.P.; Giovanella, L. SARS-CoV-2-related immune-inflammatory thyroid disorders: Facts and perspectives. Expert. Rev. Clin. Immunol. 2021, 17, 737–759. [Google Scholar] [CrossRef] [PubMed]
- Speer, G.; Somogyi, P. Thyroid complications of SARS and coronavirus disease 2019 (COVID-19). Endocr. J. 2021, 68, 129–136. [Google Scholar] [CrossRef]
- Lui, D.T.W.; Lee, C.H.; Chow, W.S.; Lee, A.C.H.; Tam, A.R.; Fong, C.H.Y.; Law, C.Y.; Leung, E.K.H.; To, K.K.W.; Tan, K.C.B.; et al. Thyroid Dysfunction in Relation to Immune Profile, Disease Status, and Outcome in 191 Patients with COVID-19. J. Clin. Endocrinol. Metab. 2021, 106, e926–e935. [Google Scholar] [CrossRef] [PubMed]
- Addeo, A.; Friedlaender, A. Cancer and COVID-19: Unmasking their ties. Cancer Treat. Rev. 2020, 88, 102041. [Google Scholar] [CrossRef]
- Kuderer, N.M.; Choueiri, T.K.; Shah, D.P.; Shyr, Y.; Rubinstein, S.M.; Rivera, D.R.; Shete, S.; Hsu, C.-Y.; Desai, A.; de Lima Lopes, G., Jr.; et al. COVID-19 and Cancer Consortium. Clinical impact of COVID-19 on patients with cancer (CCC19): A cohort study. Lancet 2020, 395, 1907–1918. [Google Scholar] [CrossRef]
- Tagliamento, M.; Agostinetto, E.; Bruzzone, M.; Ceppi, M.; Saini, K.S.; de Azambuja, E.; Punie, K.; Westphalen, C.B.; Morgan, G.; Pronzato, P.; et al. Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: A systematic review and meta-analysis. Crit. Rev. Oncol. Hematol. 2021, 163, 103365. [Google Scholar] [CrossRef] [PubMed]
- Luo, J.; Rizvi, H.; Preeshagul, I.R.; Egger, J.V.; Hoyos, D.; Bandlamudi, C.; McCarthy, C.G.; Falcon, C.J.; Schoenfeld, A.J.; Arbour, K.C.; et al. COVID-19 in patients with lung cancer. Ann. Oncol. 2020, 31, 1386–1396. [Google Scholar] [CrossRef]
- Benderra, M.-A.; Aparicio, A.; Leblanc, J.; Wassermann, D.; Kempf, E.; Galula, G.; Bernaux, M.; Canellas, A.; Moreau, T.; Bellamine, A.; et al. Clinical Characteristics, Care Trajectories and Mortality Rate of SARS-CoV-2 Infected Cancer Patients: A Multicenter Cohort Study. Cancers 2021, 13, 4749. [Google Scholar] [CrossRef]
- Tao, S.-L.; Wang, X.-M.; Feng, Y.-G.; Kang, P.-M.; Li, Q.-Y.; Sun, T.-Y.; Tan, Q.-Y.; Deng, B. Is the presence of lung injury in COVID-19 an independent risk factor for secondary lung cancer? Med. Hypotheses 2020, 143, 110074. [Google Scholar] [CrossRef]
- Davis, P.J.; Lin, H.Y.; Hercbergs, A.; Keating, K.A.; Mousa, S.A. Coronaviruses and Integrin αvβ3: Does Thyroid Hormone Modify the Relationship? Endocr. Res. 2020, 45, 210–215. [Google Scholar] [CrossRef] [PubMed]
- Deligiorgi, M.V.; Siasos, G.; Vakkas, L.; Trafalis, D.T. Charting the Unknown Association of COVID-19 with Thyroid Cancer, Focusing on Differentiated Thyroid Cancer: A Call for Caution. Cancers 2021, 13, 5785. [Google Scholar] [CrossRef] [PubMed]
- Derosa, L.; Melenotte, C.; Griscelli, F.; Gachot, B.; Marabelle, A.; Kroemer, G.; Zitvogel, L. The immuno-oncological challenge of COVID-19. Nat. Rev. Cancer 2020, 1, 946–964. [Google Scholar] [CrossRef]
- Available online: https://www.ncbi.nlm.nih.gov/research/coronavirus (accessed on 21 December 2021).
Property | DIO1 | DIO2 | DIO3 |
---|---|---|---|
Reaction catalyzed | Deiodination of both outer and inner rings of iodothyronines | Deiodination of the outer, phenolic ring | Deiodination of the inner tyrosine ring |
Localization | Plasma membrane | Endoplasmic reticulum | Plasma membrane |
Tissue distribution | Thyroid gland, liver, pituitary, kidney | Thyroid gland, brain, pituitary skeletal muscle, brown adipose tissue | Brain, pancreas, fetal tissues, placenta |
Action |
|
|
|
➢ Transformation of rT3 to T2 | |||
Substrates a | rT3 > T4 >T3 | T4 > rT3 | T3 > T4 |
Hypothyroidism | ↓ | ↑ | ↓ |
Hyperthyroidism | ↑ | ↓ | ↑ |
Ref. | Materials | Interventions/ Methods | Results |
---|---|---|---|
[93] | Murine 3LL tumor model. |
|
|
|
| ||
|
| ||
| |||
[94] | Athymic nude mouse model of lung adenocarcinoma. |
|
|
|
| ||
|
| ||
[95] | 18 SCLC and 29 NSCLC cell lines. |
|
|
[96] | Human NCI-H522 NSCLC cells and NCI-H510A SCLC cells. |
|
|
[97] | Cultured human NSCLC H1299 cells in vitro. |
|
|
Tumor cell implants in the fertilized CAM system. |
| ||
Xenografts of H1299 cells in nude mouse. | |||
[98] | NSCLC (H522) cells. |
|
|
|
| ||
[99] | Murine 3LL tumor model. |
|
|
|
| ||
|
| ||
| |||
[100] | Murine 3LL tumor model. |
|
|
|
| ||
| |||
| |||
Ref. | Type and Aim of Study | Results |
---|---|---|
[6] | Case report of a 69-years-old male patient with metastatic NSCLC treated with radiation and chemotherapy with amiodarone-induced myxedema coma. |
|
[101] | Retrospective case control study of 1979 patients with NSCLC and SCLC (stages I–IV) to assess the incidence and the prognostic significance of primary hypothyroidism. |
|
[102] | A research study of 9 NSCLC patients and 11 healthy individuals to assess the pattern of HPT axis function in a 24 h sleep-wake schedule. |
|
[103] | Prospective study of 29,691 individuals without previously known thyroid disease to assess the association of thyroid function with cancer risk. |
|
[104] | Prospective, population-based, cohort study of 10,318 individuals to assess the association of thyroid function with cancer risk. |
|
[105] | Prospective cohort study of a community-dwelling population of 3649 participants aged 25–84 years in Western Australia to assess the association of thyroid function with cancer risk. |
|
[106] | Research study of correlation of sales of LT4 in 2009 with the prevalence of lung cancer (as well as breast, colorectal, gastric and cancer) in women of 30–84 years-old in 18 Italian regions treated with LT4 during 2010. |
|
[95] | Research study of analysis of TRβ1 methylation in 116 NSCLC surgical specimens. |
|
Ref | Patients/Methods | Results |
---|---|---|
[113] | Prospective study of 51 patients with advanced NSCLC treated with pembrolizumab in the setting of KEYNOTE-001 (Clinical Trial Registry ID: NCT01295827). |
|
[114] | Prospective study of 134 patients with histologically confirmed stage IIIB/IV NSCLC treated with nivolumab due to disease progression after one or two lines of treatment. |
|
[115] | Retrospective analysis of 111 NSCLC patients treated with nivolumab. |
|
[116] | Retrospective analysis of 126 patients with advanced solid tumors (NSCLC, renal cell carcinoma, metastatic melanoma) treated with PD-1 inhibitors (nivolumab, pembrolizumab). |
|
[118] | Systematic review of 24 eligible trials enrolling 6,678 patients treated with sunitinib. A meta-analysis of seven randomized trials enrolling 2,787 subjects. |
|
[120] | Prospective observational study of 50 NSCLC patients treated with EGFR and ALK inhibitors over a period of 15 mo. |
|
[121] | Retrospective review of 197 patients with various cancer types including NSCLC from 4 clinical trials that included therapy with at least one TKI agent. |
|
[122] | Phase III ALTER-0303 trial (Clinical Trial Registry ID: NCT 02388919). |
|
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Deligiorgi, M.V.; Trafalis, D.T. The Intriguing Thyroid Hormones–Lung Cancer Association as Exemplification of the Thyroid Hormones–Cancer Association: Three Decades of Evolving Research. Int. J. Mol. Sci. 2022, 23, 436. https://doi.org/10.3390/ijms23010436
Deligiorgi MV, Trafalis DT. The Intriguing Thyroid Hormones–Lung Cancer Association as Exemplification of the Thyroid Hormones–Cancer Association: Three Decades of Evolving Research. International Journal of Molecular Sciences. 2022; 23(1):436. https://doi.org/10.3390/ijms23010436
Chicago/Turabian StyleDeligiorgi, Maria V., and Dimitrios T. Trafalis. 2022. "The Intriguing Thyroid Hormones–Lung Cancer Association as Exemplification of the Thyroid Hormones–Cancer Association: Three Decades of Evolving Research" International Journal of Molecular Sciences 23, no. 1: 436. https://doi.org/10.3390/ijms23010436